9 results about "Antibody hypervariable region" patented technology

This invention relates to the field of bioengineering technology, specifically to a recombinant adenovirus displaying a large antigen fragment on its capsid surface, its construction method, and its applications. The HVR1 and HVR5 regions of the hexon hypervariable region of this virus are replaced by gene fragments containing exogenous genes; each exogenous gene fragment has a flexible linker attached to both ends, and the gene sequence of the flexible linker is shown in SEQ ID No. 1. By precisely locating the naturally variable HVR1 and HVR5 loop regions exposed on the surface of the hexon protein as insertion sites, and supplementing them with flexible linkers, the core problem of exogenous sequence insertion disrupting the stability of the hexon structure is successfully solved. This allows for stable packaging to produce viral particles with high titers and infectivity, enabling the development of a new generation of highly efficient and safe capsid-displaying adenovirus vaccines.

The invention discloses a microbial community identification method and system, and particularly relates to the technical field of microbiomics. A hidden Markov model database constructed on the basis of multiple types of ribosome RNA sequences is adopted for global search, a huge whole genome database in the prior art is replaced, and the size of the database is reduced; moreover, the hypervariable region sequence is extracted from the identified ribosome RNA sequence in a targeted manner, and the extracted sequence data and the quality information in the original sequencing data are pasted back, so that the hypervariable region sequence file containing the complete quality information is generated. The sequence data contains sequence information for identification, and a ribosome RNA marker gene sequence can be accurately identified and extracted from metagenome or metatranscriptome sequencing data; the original sequencing data can be used for a traditional amplicon analysis process, and can also support downstream deep analysis, so that seamless connection with the traditional amplicon analysis process is realized.

The disclosure relates, inter alia, to recombinant adenoviruses having capsid proteins engineered to include an albumin-binding moiety such that the albumin-binding moiety is present on the outer surface of the recombinant adenovirus capsids. Also described are pharmaceutical compositions comprising the recombinant adenoviruses, and methods of using the recombinant adenoviruses to treat genetic diseases and disorders.

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.

The present invention provides a library containing synthetic polynucleotides encoding antibody heavy chains (e.g., heavy chains of dynamic human antibodies), as well as antibody heavy chains, antibodies, cells, animals, methods, and kits related thereto. [Solution] Provided herein is a library containing polynucleotides, one of which encodes an antibody heavy chain containing specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein is a library containing polynucleotides encoding a plurality of unique antibodies, each antibody containing a heavy chain variable region and a light chain variable region. Also provided relating to the antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods for constructing antibody libraries, kits, and methods for producing bispecific antibodies.

This application describes a technology relating to treating neurofibromatosis type 1 and particularly, but not exclusively, to compositions and methods for gene replacement therapy treatments of patients having NF1-related tumors, for example, new recombinant adeno-associated virus vectors comprising a neurofibromatosis type 1 GAP-related domain fused to a Ras hypervariable region and use thereof to treat neurofibromatosis type 1.

This invention relates to the field of biological protein application technology, and discloses the application of flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. The amino acid sequence of flagellin hypervariable region H is shown in SEQ ID NO.3, and the nucleotide sequence of the gene encoding flagellin hypervariable region H is shown in SEQ ID NO.4. This invention also discloses an expression cassette, recombinant vector, recombinant cells, or recombinant bacteria containing the gene encoding flagellin hypervariable region H. This invention uses the aforementioned flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. This invention connects flagellin hypervariable region H to an antigenic epitope to obtain a fusion protein. Compared with existing technologies, the solubility and activity of the fusion protein are improved. Simultaneously, this invention overcomes the expression form of inclusion bodies in existing E. coli expression systems, eliminating the need for subsequent refolding and assembly, thus simplifying the vaccine preparation process.

The present application provides an anti-human CD153 monoclonal antibody, or a binding fragment thereof, that specifically binds to human CD153 and inhibits the intermolecular interaction between human CD153 and CD30. The present application further provides: a chimeric antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signal transduction domain wherein the extracellular antigen binding domain comprises a single-chain antibody having a heavy chain hypervariable region and a light chain hypervariable region which are the same as those of the monoclonal antibody of the present application; the invention also discloses a CAR-T cell for expressing the chimeric antigen receptor. The monoclonal antibody, the binding fragment of the monoclonal antibody and the CAR-T cell can be used for treating or preventing diseases related to CD153, such as multiple sclerosis. The invention provides the anti-human CD153 monoclonal antibody or the binding fragment of the anti-human CD153 monoclonal antibody which specifically binds to human CD153 and inhibits intermolecular interaction between the human CD153 and CD30. The present application further provides: a chimeric antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signal transduction domain wherein the extracellular antigen binding domain comprises a single-chain antibody having a heavy chain hypervariable region and a light chain hypervariable region which are the same as those of the monoclonal antibody of the present application; the invention also discloses a CAR-T cell for expressing the chimeric antigen receptor. The monoclonal antibody, the binding fragment thereof and the CAR-T cell can be used for treating or preventing diseases related to CD153, such as multiple sclerosis.

The application discloses a kind of paragallinarievaccines and preparation method thereof, the paragallinarievaccines include A type paragallinarie, B type paragallinarie and C type paragallinarie HMTp210 hypervariable region protein and avian pathogenic escherichia coli ghost.The application uses three serotypes HMTp210 hypervariable region recombinant protein and avian pathogenic escherichia coli ghost (especially O78 type avian pathogenic escherichia coli ghost) in combination, synergistically enhances humoral and cellular immunity, provides more broad-spectrum protection, while reaching the protection effect equivalent to white oil adjuvant, significantly improves injection safety, avoids the granuloma and other side reactions of white oil adjuvant, realizes the technical goal of "equivalent protection, better safety".